Over 1.4 million Australians are living with Chronic Obstructive Pulmonary Disease, or COPD, with as many as one in 20 people over the age of 55 affected by the condition. Although understanding of COPD has improved significantly in recent years, we are constantly seeking new avenues to explore in our relentless pursuit for better breathing.
Imagine what it would feel like to take a breath when your lungs were already full of air. Try this. Take in a deep breath. Hold it in for three seconds and don’t exhale. Now try taking another breath. And another one. It’s not easy is it? This is a feeling some people with Chronic Obstructive Pulmonary Disease (COPD) live with every day of their lives.
Simple activities, like walking up stairs or on a gradual incline, are an everyday struggle for people living with COPD. Most people don’t spend time thinking about their breathing, but for some it consumes their daily life.
COPD is a common but serious lung disease that limits airflow to the lungs and is ranked as one of the most disabling conditions in the world. It affects individual patients in different ways and its impact can change over time. Today, around 384 million people have COPD globally. It is estimated to become the third leading cause of death worldwide by 2030.
GSK’s commitment to respiratory disease
We have a long heritage in research and innovation around respiratory disease. Over the past 40 years, we have invested more in respiratory research than any other company.
We remain committed to developing treatments that help patients here in Australia and worldwide who suffer from breathing-related illnesses do more, feel better and live longer. This requires a deep understanding of respiratory disease, a promise to furthering the science, and an awareness that every patient’s experience is different.